Kathleen Hunter
Adult Health · Amarillo, TXNPI 1962144543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,381 and has fallen 95.3% since, to $65 in 2024.
Across 88 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$256
- AstraZeneca$128
- Seagen Inc.$124
- Eisai Inc.$88
- Sanofi$79
- Lilly USA, LLC$79
- plus $1K from 36 others
What the payments were for
- Food & beverage$1,77691%
- Education$1739%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 8 | $256 |
| AstraZeneca(2 entities) | 6 | $128 |
| Seagen Inc. | 3 | $124 |
| Eisai Inc. | 5 | $88 |
| Sanofi | 3 | $79 |
| Lilly USA, LLC | 3 | $79 |
| Pfizer | 4 | $74 |
| Novartis | 3 | $68 |
| Genentech USA, Inc. | 2 | $64 |
| Bristol Myers Squibb | 3 | $63 |
| CTI Biopharma Corp. | 3 | $63 |
| Merck | 3 | $61 |
| Taiho Oncology, Inc. | 2 | $54 |
| Karyopharm Therapeutics Inc. | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Array Biopharma Inc | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Olympus America Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $36 |
| Organon | 3 | $35 |
| EMD Serono, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $31 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Sobi, Inc | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Global Blood Therapeutics, Inc. | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $19 |
| Myovant Sciences Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| Octapharma USA, Inc. | 1 | $12 |
How this compares
$1,949 in reported general payments places this provider in the 75th percentile of 933 adult health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $16,485 |
| JardianceEmpagliflozin | 37 | $7,936 |
| XareltoRivaroxaban | 24 | $5,144 |
| EliquisApixaban | 19 | $3,965 |
| GemtesaVibegron | 16 | $3,746 |
| TrintellixVortioxetine Hydrobromide | 19 | $3,446 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $3,394 |
| EntrestoSacubitril/Valsartan | 13 | $3,338 |
| TradjentaLinagliptin | 12 | $2,382 |
| Atorvastatin Calcium | 42 | $1,454 |
| Gabapentin | 66 | $1,400 |
| Sertraline Hcl | 57 | $1,400 |
| Rosuvastatin Calcium | 31 | $1,374 |
| Mirabegron ErMirabegron | 25 | $1,272 |
| Levothyroxine Sodium | 76 | $1,241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $31 | $5,14424 claims |
| PfizerEliquis | $74 | $3,96519 claims |
| NovartisEntresto | $68 | $3,33813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 933 adult health providers in Texas.
Other adult health in Amarillo
- Misty SheddAllen$863K
- Melodie YoungDallas$700K
- Cynthia BedellPlano$168K
- Elizabeth Wedberg SivamAustin$71K
- Mary SalazarSan Antonio$68K
- Eric KlappholzDallas$44K
- Christin TouchetKingwood$43K
- Yulia LyuboslavskyAustin$36K
- Meghan MurphyAustin$29K
- Sandra CareyGrapevine$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.